US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Myriad Genetics Inc (MYGN)
Myriad Genetics Inc (MYGN) ニュース

MYGN

Myriad Genetics (MYGN)

Myriad Genetics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MYGN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/17	05 : 05	GlobeNewswire Inc.	New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/16	06 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/16	06 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/16	05 : 24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/15	05 : 26	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/14	05 : 24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/14	01 : 14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/08	21 : 23	IH Market News	Reddit Rises 15% After First Quarterly Report, Upstart and Twilio Plunge Due to Weak Q2 Forecast, and More in Earnings	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/08	21 : 14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/08	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/08	05 : 05	GlobeNewswire Inc.	Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/07	22 : 00	GlobeNewswire Inc.	Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business	NASDAQ:MYGN	Myriad Genetics Inc
2024/05/01	05 : 05	GlobeNewswire Inc.	Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024	NASDAQ:MYGN	Myriad Genetics Inc
2024/04/17	21 : 00	GlobeNewswire Inc.	Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor	NASDAQ:MYGN	Myriad Genetics Inc
2024/04/16	22 : 15	GlobeNewswire Inc.	New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen	NASDAQ:MYGN	Myriad Genetics Inc
2024/04/09	21 : 00	GlobeNewswire Inc.	Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	NASDAQ:MYGN	Myriad Genetics Inc
2024/03/22	10 : 40	GlobeNewswire Inc.	Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	NASDAQ:MYGN	Myriad Genetics Inc
2024/03/21	05 : 05	GlobeNewswire Inc.	Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device	NASDAQ:MYGN	Myriad Genetics Inc
2024/03/05	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/28	22 : 31	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/28	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/28	06 : 05	GlobeNewswire Inc.	Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fo	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/27	23 : 15	GlobeNewswire Inc.	Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/27	06 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/27	06 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/22	06 : 05	GlobeNewswire Inc.	Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/16	06 : 05	GlobeNewswire Inc.	Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/15	06 : 47	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/14	22 : 24	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MYGN	Myriad Genetics Inc
2024/02/09	00 : 14	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MYGN	Myriad Genetics Inc

Showing the most relevant articles for your search:NASDAQ:MYGN

1 2 3 4 5 6 7 8 9 10 次へ >>

ROC Energy Acquisition

CI Enhanced Government B...

Morgan Stanley Bank Na C...

Estrella Resources

Golden Cariboo Resources

Megacap Portfolio Series...

Hallwood Realty Partners

Wheaton Precious Metals

FirmaChain Token

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約